New Clinical Use for Gocovri

Adamas announced that the Food and Drug Administration (FDA) approved Gocovri for a second indication – as an add-on treatment to carbidopa/levodopa in Parkinson’s disease (PD) patients who are experiencing OFF episodes.

Previously, Gocovri was only approved for treatment of Levodopa-induced dyskinesias.

You can learn more about managing dyskinesias and OFF episodes in this webinar.

This additional indication acknowledges that Gocovri now has two clinical uses and opens up another option for those who need help with management of OFF episodes. Even more exciting is the fact that some people with PD have both episodes of dyskinesia and OFF during the day. Gocovri could be a potential option to address both these issues simultaneously.

As always, please consult your neurologist about any new medications and to determine if Gocovri is a reasonable medication for you to try.

APDA welcomes this new addition to the collection of medications available to treat the symptoms of PD. Each new medication provides more ways to tailor treatment to each specific person.